Drug Diversion Charges and Michigan Licensed Healthcare Professionals: Defense Strategy and Licensing Consequences

A Michigan licensed healthcare professional facing a drug diversion charge is defending three things at once: the criminal case, the professional license, and the DEA registration that makes clinical practice possible.

Those three tracks move on different timelines, respond to different decision-makers, and can each produce a career-ending outcome independently of the others.

A felony conviction for a controlled substance offense triggers mandatory DEA revocation under federal law, mandatory OIG exclusion from Medicare and Medicaid, and LARA licensing proceedings, each of which operates automatically or near-automatically, regardless of what the criminal court imposes.

The most consequential decisions in a drug diversion case are made before any charge is filed, and often before the professional knows an investigation exists.

This page addresses drug diversion charges and their specific implications for licensed healthcare professionals in Michigan. The consequence framework that governs all licensed healthcare professionals, including the three categories of consequence that flow from any criminal conviction and how criminal defense strategy must be coordinated with healthcare licensing counsel from the investigation stage, is developed in the firm's analysis of criminal charges and licensed healthcare professionals in Michigan.

How Drug Diversion Investigations Begin

Drug diversion investigations of licensed healthcare professionals rarely begin with a complaint. Instead, long before a complaint or indictment is filed, they begin with data.

The DEA's Office of Diversion Control, the Michigan Department of Licensing and Regulatory Affairs, and federal prosecutors use the Michigan Automated Prescription System, known as MAPS, to identify prescribing and dispensing patterns that diverge from statistical norms within a provider's specialty, geography, and patient population.

A physician writing opioid prescriptions at volumes that exceed peer comparators, a pharmacist dispensing Schedule II medications in patterns inconsistent with the surrounding prescriber base, or a nurse whose patient medication records show unexplained discrepancies will generate a data flag before any investigator makes contact.

DEA Diversion Investigators are specifically trained to identify healthcare-specific diversion indicators and are distinct from traditional law enforcement agents. Their investigations frequently involve months of data analysis, prescription database review, and inspection of DEA registrant records before any overt investigative step is taken.

In some cases, investigators coordinate covertly with the practitioner's employer, pharmacy benefit manager, or hospital compliance department before making any direct contact with the practitioner.

The first overt contact, a DEA Diversion Investigator requesting a voluntary interview, an on-site inspection of controlled substance records, or a grand jury subpoena for patient files, typically arrives after the government's core theory has already been developed.

Understanding what the government already has, and what it is still trying to develop, requires immediate retention of criminal defense counsel before any response is made.

The Federal and State Statutory Framework

Drug diversion by a licensed healthcare professional can be charged under federal and state law simultaneously, and the choice of charging authority has significant consequences for both the criminal sentence and the professional licensing outcome.

Understanding which statutes are implicated, and what each requires the government to prove, is the foundation of effective defense strategy.

Federal Charges

The primary federal statute is 21 U.S.C. § 841(a)(1), which prohibits the knowing or intentional manufacture, distribution, or dispensing of a controlled substance. For healthcare professionals, the government charges under this statute when it alleges that prescriptions were issued outside the usual course of professional practice or without a legitimate medical purpose.

That standard turns not on whether a valid DEA registration existed at the time, but instead, on clinical documentation, prescribing context, and expert testimony about professional norms.

Prescription fraud and acquisition of controlled substances by misrepresentation or deception are charged under 21 U.S.C. § 843, which also carries felony exposure. A pharmacist who alters a prescription to divert inventory, a nurse who forges a physician's signature to obtain controlled substances for personal use, or a practitioner who uses a colleague's DEA registration number without authorization each potentially faces a distinct federal charge under this statute.

State Charges

Michigan law addresses controlled substance diversion under MCL § 333.7401, which prohibits the manufacture, delivery, or possession with intent to deliver controlled substances, and MCL § 333.7403, which addresses unlawful possession.

State charges are often brought alongside or instead of federal charges, particularly when the diversion involves personal use rather than distribution to third parties, and the state prosecution may be coordinated with LARA licensing proceedings on a parallel track.

DEA Registration: The Consequence That Can End a Career Before Sentencing

The DEA registration consequence of a controlled substance felony is among the most severe and least reversible professional consequences a healthcare provider can face.

Under 21 U.S.C. § 824(a)(2), the DEA may revoke or suspend the registration of any practitioner convicted of a felony under any law relating to a controlled substance, and the DEA treats that authority as effectively mandatory upon a qualifying felony conviction.

Without a DEA registration, a physician cannot lawfully prescribe Schedule II through Schedule V controlled substances. For most clinical practices in Michigan, that restriction eliminates the ability to practice in any specialty involving pain management, anesthesia, psychiatry, or the treatment of addiction.

Pharmacists require DEA registration to dispense controlled substances, and nurse practitioners with prescriptive authority face the elimination of that authority when the underlying registration is revoked.

The strategic implication for criminal defense is direct: the specific charge to which a practitioner pleads, and whether it constitutes a felony related to controlled substances, determines whether DEA revocation is triggered.

That determination must be a primary design constraint in any plea negotiation. Once a qualifying felony plea is entered, the DEA registration consequence is locked in and cannot be reversed by cooperation, mitigation at sentencing, or any subsequent proceeding.

LARA Licensing Consequences

The LARA licensing consequence of a drug diversion charge runs on a parallel and independent track from both the criminal case and the DEA proceeding.

Upon receiving notice of a controlled substance conviction through the self-report required by MCL § 333.16222(3) or through the court clerk's report under MCL § 769.16a(7), LARA will initiate disciplinary proceedings before the board governing the relevant profession.

For a drug diversion conviction, the licensing board's analysis focuses on three questions: whether the conduct reflects a substance use disorder, whether the practitioner poses a public safety risk if allowed to continue practicing, and whether the conduct underlying the charge reflects dishonesty or a character deficiency independent of any clinical diagnosis.

Those questions are answered by the criminal record alongside the full record of the criminal matter, the plea, the sentencing record, the treatment documentation, and the remediation steps taken before the licensing board convenes.

A practitioner who has genuinely engaged with substance use treatment, who can demonstrate insight into the conduct and its professional implications, and who arrives at the licensing proceeding with a documented remediation record is in a materially different position than one who has not.

Patrick Barone's analysis of how criminal accusations create potentially debilitating collateral consequences for licensed healthcare professionals, published through the State Appellate Defender Office, develops the framework that governs those proceedings.

OIG Exclusion and Federal Program Consequences

A felony conviction for an offense relating to controlled substances triggers mandatory OIG exclusion from Medicare, Medicaid, and all federal healthcare programs under 42 U.S.C. § 1320a-7(a)(4).

That exclusion carries a minimum five-year period, operates automatically upon conviction, and bars the practitioner from any participation in federal healthcare programs, including employment by an entity that bills those programs.

For many licensed healthcare professionals in Michigan, mandatory OIG exclusion is the practical end of clinical practice, because it eliminates federal program billing, which most practice settings depend on, regardless of whether the state license survives.

The OIG exclusion, the DEA revocation proceeding, and the LARA disciplinary track each operate independently, and each can reach its conclusion before the others, meaning a practitioner can face active professional consequences on three separate fronts simultaneously while the criminal case is still pending.

The reporting cascade moves quickly. The court clerk files its report to LARA within twenty-one days under MCL § 769.16a(7), LARA initiates disciplinary proceedings, the OIG issues its exclusion notice, and the DEA initiates revocation proceedings.

Each of those tracks is governed by its own procedures, timelines, and standards, and none of them waits for the others to conclude.

The Substance Use Evaluation, HPRP, and the Clinical Record

Not every licensed healthcare professional who faces a drug diversion charge has a substance use disorder. A clinical evaluation conducted by a qualified evaluator, using the diagnostic criteria developed under the DSM-5, is the foundation for any informed strategy decision about whether and how the substance use issue is addressed in the criminal case and the licensing proceeding.

Patrick Barone and Dr. Elizabeth Corby co-authored an analysis of the DSM-5 for substance use disorders, published through the State Appellate Defender Office, addressing the clinical and legal framework governing how substance use disorder diagnoses are made, what they require the evaluator to establish, and how they interact with the criminal sentencing and licensing processes.

Where the evaluation identifies a substance use disorder, the decision about HPRP must be made strategically and in coordination between criminal defense counsel and healthcare licensing counsel.

HPRP is a monitoring program administered under MCL § 333.16105a that licensing boards may require as a condition of continued licensure, and HPRP contracts frequently carry a minimum monitoring period of three years and can become five years or more depending on the clinical findings and the board's assessment of public safety risk.

Voluntary engagement with HPRP before the criminal case is resolved can demonstrate to the licensing board a willingness to address the underlying issue, which is among the most significant factors in the board's fitness assessment.

The same engagement, if coordinated carelessly with the criminal defense, can produce statements or records that the government seeks to use in the criminal proceeding, a risk that is eliminated when criminal defense counsel and licensing counsel are working together from the beginning.

Sentence Mitigation for Licensed Healthcare Professionals Facing Drug Diversion Charges

Sentence mitigation in drug diversion cases involving licensed healthcare professionals requires a narrative that addresses both the conduct and its professional context and does so in a way that is clinically grounded, personally authentic, and structurally effective for three separate audiences: the sentencing court, the licensing board, and the DEA.

This firm's approach to sentencing mitigation is developed in formal collaboration with Doug Passon, an internationally recognized sentencing mitigation expert whose work in this field was identified by the Wall Street Journal as pioneering.

Patrick Barone and Mr. Passon co-authored Using Psychodrama for Sentencing Mitigation, published in the NACDL Champion in July 2024, which addresses the use of psychodramatic techniques to help defendants access authentic material that moves beyond credential recitation to the lived experience that sentencing courts find most meaningful.

For a licensed healthcare professional whose diversion is rooted in a substance use disorder, the mitigation narrative has a specific structure the court needs to understand: how a professional with significant clinical training and access to treatment arrived at the conduct that brought them to sentencing.

The answer to that question, delivered with genuine insight, clinical grounding, and personal authenticity, is the most compelling mitigation available, and it must be built carefully from the earliest stage of the criminal matter.

That authenticity cannot be manufactured after a conviction. It must be built under the guidance of counsel who understands both the clinical dimensions of substance use disorder and the professional context in which the diversion occurred.

The mitigation presentation constructed for the sentencing court is also the record the licensing board and the DEA will evaluate, those three tracks must be built together, from the beginning.

What Michigan Licensed Healthcare Professionals Should Know About Early Retention of Counsel

The practitioners who fare best in drug diversion matters are, without exception, those who retain criminal defense counsel with federal healthcare regulation experience at the investigation stage, before any charge is filed, before any voluntary interview is conducted, and before any institutional disclosure is made.

Patrick Barone's analysis of alcohol- and drug-related charges and their specific implications for licensed healthcare professionals in Michigan, published in the Michigan Bar Journal in October 2013, remains a foundational resource for understanding how those charges interact with professional licensing.

By the time a DEA Diversion Investigator makes first contact, the government's investigative record has typically been assembled over months. The practitioner who responds without counsel has no way of knowing what the government already has, what theory it is pursuing, or what statements would be used against them at trial or in a licensing proceeding.

Retaining counsel at the investigation stage preserves suppression arguments, controls the evidentiary record before it is fixed, and allows a coordinated response to any institutional disclosure obligations the practitioner faces simultaneously.

Frequently Asked Questions: Drug Diversion Charges and Michigan Licensed Healthcare Professionals

Next Steps for Michigan Licensed Healthcare Professionals Facing Drug Diversion Charges

If you are a licensed healthcare professional in Michigan facing a drug diversion investigation, a DEA inquiry, a controlled substance records audit, or any formal charge relating to a controlled substance, the most important step is retaining criminal defense counsel who understands the federal regulatory framework, the DEA registration consequence, and the professional licensing consequences that attach to a qualifying conviction.

At Barone Defense Firm, we represent licensed healthcare professionals in drug diversion matters where the criminal defense strategy must account for the DEA registration consequence, the OIG exclusion threshold, and the licensing proceeding from the first day of representation.

We engage healthcare licensing specialists and sentencing mitigation expertise as part of the defense team from the earliest possible stage, coordinating criminal defense strategy across all three consequence tracks simultaneously.

To schedule a confidential consultation, call 1-877-ALL-MICH (877-255-6424), or contact us online. Consultations are available around the clock.

This page was written by Patrick Barone, founding attorney of Barone Defense Firm in Birmingham, Michigan. Patrick has represented licensed healthcare professionals at the intersection of criminal defense and professional licensing consequences for more than three decades.

His published analyses include Representing Licensed Health Care Professionals Accused of Alcohol- or Drug-Related Crimes, published in the Michigan Bar Journal in October 2013, and Criminal Accusations Cause Health Care Professionals to Face Potentially Debilitating Collateral Consequences, published through the State Appellate Defender Office.

His analysis of the DSM-5 for substance use disorders, co-authored with Dr. Elizabeth Corby and published through the State Appellate Defender Office, addresses the clinical and legal framework governing substance use evaluations in criminal and licensing proceedings.

His analysis of the use of psychodrama in sentencing mitigation, co-authored with internationally recognized sentencing mitigation expert Doug Passon and published in the NACDL Champion in July 2024, addresses the development of authentic mitigation narratives in cases involving licensed professionals.

Patrick is a graduate of the Gerry Spence Trial Lawyers College, a Board Certified TEP (the highest level of certification) in psychodrama, sociometry, and group psychotherapy through the American Board of Examiners, and the only such credential holder in Michigan.

He has been recognized as a Michigan Super Lawyer continuously since 2007 and is listed in The Best Lawyers in America. The firm's federal practice covers both the Eastern and Western Districts of Michigan.